AbbVie’s ABBV-466 shows higher endoscopic remission rates than monotherapies in Phase 2a Crohn’s study
ABBV•In the Phase 2a TARGET-CD trial, endoscopic remission at Week 12 was 30.2% with AbbVie’s ABBV-466, versus 21.3% with risankizumab and 18% with trosunilimab. At Week 24, rates were 40.5%, 22.4% and 20%, respectively.
1. Trial results
In the open-label TARGET-CD trial, ABBV-466 outperformed either monotherapy on endoscopic remission in patients with moderate to severe Crohn’s disease. At Week 12, remission reached 30.2% with ABBV-466, compared with 21.3% with risankizumab and 18% with trosunilimab; by Week 24, rates were 40.5%, 22.4% and 20%, respectively.
2. Safety and enrollment
Serious adverse events occurred in 10.4% of ABBV-466 patients, 9.6% of those receiving risankizumab and 9% of those receiving trosunilimab. The trial enrolled 300 patients, 75% of whom had failed at least one advanced therapy.
